Concord Biotech LimitedQ2 FY27 Results & Financial Update
Concord Biotech Limited: Q2 FY27 consolidated results and company financials – revenue ₹309.07 Cr, PAT ₹69.57 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Concord Biotech price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Concord Biotech Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Concord Biotech Limited posted consolidated revenue of INR 309.07 crore for the quarter ended September 30, 2026, marking an increase compared to the previous quarter's revenue of INR 257.49 crore.
Total income for the period stood at INR 319.24 crore, expanding from INR 270.31 crore reported in the preceding quarter.
Profit before tax (PBT) reached INR 96.14 crore, registering growth over the INR 77.07 crore recorded in the first quarter of the fiscal year.
Consolidated profit after tax (PAT) for Q2 FY27 was reported at INR 69.57 crore, compared to INR 57.70 crore in the June 2026 quarter.
Basic and diluted earnings per share (EPS) rose to INR 6.65 for the quarter, compared to INR 5.52 in the preceding period.
The financial performance reflects sequential top-line expansion alongside increased profitability across the consolidated business operations.
01 · Business model
What does Concord Biotech do?
Concord Biotech Limited operates as a biopharmaceutical company specializing in the development and manufacturing of complex fermentation-based active pharmaceutical ingredients (APIs) and finished formulations.
The company serves global pharmaceutical markets, supplying its specialized portfolio across multiple regulated geographies through advanced manufacturing facilities.
Its operational model centers on complex bioprocess technology, leveraging fermentation capabilities to produce high-barrier products for diverse therapeutic segments.
02 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹309.07 Cr | ₹257.49 Cr |
| Total income | ₹319.24 Cr | ₹270.31 Cr |
| Profit before tax | ₹96.14 Cr | ₹77.07 Cr |
| Profit after tax | ₹69.57 Cr | ₹57.70 Cr |
| EPS | ₹6.65 | ₹5.52 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 22.5% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 31.1% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹10.17 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Consolidated revenue from operations advanced to INR 309.07 crore in Q2 FY27 from INR 257.49 crore in Q1 FY27.
Total income reached INR 319.24 crore, supported by operational revenue alongside other income of INR 10.17 crore and interest income of INR 0.62 crore.
What drove margins
Net profit margin stood at approximately 22.51% for the current quarter, showing an expansion compared to the preceding quarter.
Depreciation and amortisation expenses were recorded at INR 18.38 crore, while finance costs remained minimal at INR 0.03 crore for the quarter.
04 · Reported developments
What changed operationally
The company demonstrated consistent sequential growth in revenue, operating profit before tax, and net profit compared to the June 2026 quarter.
05 · Items worth noticing
The line items that can distort a quick read
The company recorded provisions of INR 12.44 crore and tax expenses of INR 25.91 crore for the quarter.
06 · Beyond the numbers
What changed beyond the numbers
Reported update
Statutory Disclosure
Financial statements were submitted through the official exchange filing portal under Indian Accounting Standards (Ind AS) on a consolidated basis.
07 · Previous-quarter changes
What changed since the previous quarter
Revenue expanded from INR 257.49 crore in Q1 FY27 to INR 309.07 crore in Q2 FY27.
PAT increased from INR 57.70 crore in Q1 FY27 to INR 69.57 crore in Q2 FY27.
08 · Key Q&A
The quarter, answered directly
What does Concord Biotech do?
Concord Biotech Limited operates as a biopharmaceutical company specializing in the development and manufacturing of complex fermentation-based active pharmaceutical ingredients (APIs) and finished formulations.
What is the clearest takeaway from Q2 FY27?
Concord Biotech Limited posted consolidated revenue of INR 309.07 crore for the quarter ended September 30, 2026, marking an increase compared to the previous quarter's revenue of INR 257.49 crore.
What drove revenue or demand?
Consolidated revenue from operations advanced to INR 309.07 crore in Q2 FY27 from INR 257.49 crore in Q1 FY27.
What mattered most for margins or profitability?
Net profit margin stood at approximately 22.51% for the current quarter, showing an expansion compared to the preceding quarter.
What changed operationally beyond the headline numbers?
Financial statements were submitted through the official exchange filing portal under Indian Accounting Standards (Ind AS) on a consolidated basis.
What should the next disclosure help confirm?
Track upcoming quarterly financial filings for revenue trajectory and margin sustainability.
09 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
10 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent Financial Disclosures: Track upcoming quarterly financial filings for revenue trajectory and margin sustainability.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.